43.92

2.86% 1.22

Exelixis Inc (EXEL)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt EXEL? Forum Prognose

Schlusskurs vom Vortag:

$42.70

Offen:

$42.89

24-Stunden-Volumen:

2.05M

Relative Volume:

0.80

Marktkapitalisierung:

$11.41B

Einnahmen:

$2.29B

Nettoeinkommen (Verlust:

$677.90M

KGV:

18.49

EPS:

2.3753

Netto-Cashflow:

$779.77M

1W Leistung:

+0.05%

1M Leistung:

-0.36%

6M Leistung:

+14.11%

1J Leistung:

+27.34%

1-Tages-Spanne:

$42.73

$44.05

1-Wochen-Bereich:

$40.92

$44.28

52-Wochen-Spanne:

$32.38

$49.62

Exelixis Inc Stock (EXEL) Company Profile

Firmenname

Exelixis Inc

Sektor

Healthcare (1111)

Branche

Biotechnology (622)

Telefon

(650) 837-7000

Adresse

1851 HARBOR BAY PARKWAY, ALAMEDA, CA

Mitarbeiter

1,077

Twitter

@exelixisinc

Nächster Verdiensttermin

2025-07-28

Neueste SEC-Einreichungen

EXEL's Discussions on Twitter

Compare EXEL vs VRTX, REGN, ARGX, ALNY, ONC

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
EXEL Exelixis Inc	43.92	11.09B	2.29B	677.90M	779.77M	2.3753
VRTX Vertex Pharmaceuticals Inc	491.47	117.98B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	803.17	82.85B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	821.96	51.58B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	314.40	40.75B	3.21B	43.57M	221.36M	0.2405
ONC Beone Medicines Ltd Adr	346.07	38.33B	4.98B	69.60M	525.67M	0.5198

Exelixis Inc Stock (EXEL) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-01-08	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2026-01-05	Herabstufung	BofA Securities	Neutral → Underperform
2025-11-18	Eingeleitet	Wolfe Research	Peer Perform
2025-11-03	Herabstufung	Guggenheim	Buy → Neutral
2025-10-21	Hochstufung	Leerink Partners	Market Perform → Outperform
2025-09-19	Fortgesetzt	Barclays	Equal Weight
2025-09-17	Fortgesetzt	Barclays	Equal Weight
2025-09-17	Eingeleitet	Goldman	Buy
2025-07-08	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2025-06-24	Hochstufung	Stephens	Equal-Weight → Overweight
2025-02-24	Herabstufung	Wells Fargo	Overweight → Equal Weight
2025-01-27	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2025-01-24	Herabstufung	Oppenheimer	Outperform → Perform
2024-12-20	Herabstufung	BMO Capital Markets	Outperform → Market Perform
2024-12-17	Herabstufung	BofA Securities	Buy → Neutral
2024-10-16	Bestätigt	RBC Capital Mkts	Outperform
2024-09-19	Eingeleitet	UBS	Neutral
2024-04-11	Herabstufung	Barclays	Overweight → Equal Weight
2023-12-19	Eingeleitet	BTIG Research	Buy
2023-12-15	Eingeleitet	Citigroup	Buy
2023-09-26	Eingeleitet	H.C. Wainwright	Buy
2023-08-22	Bestätigt	Oppenheimer	Outperform
2023-08-08	Eingeleitet	SVB Securities	Market Perform
2023-07-11	Fortgesetzt	Morgan Stanley	Equal-Weight
2023-05-10	Fortgesetzt	Piper Sandler	Overweight
2023-03-09	Eingeleitet	Wells Fargo	Overweight
2023-01-26	Eingeleitet	Credit Suisse	Outperform
2022-10-18	Eingeleitet	JMP Securities	Mkt Outperform
2022-06-24	Eingeleitet	BMO Capital Markets	Outperform
2021-11-19	Eingeleitet	Piper Sandler	Overweight
2021-11-03	Fortgesetzt	Jefferies	Buy
2021-10-07	Eingeleitet	Jefferies	Buy
2021-08-06	Bestätigt	H.C. Wainwright	Buy
2021-06-15	Eingeleitet	H.C. Wainwright	Buy
2021-05-18	Fortgesetzt	Goldman	Sell
2021-03-31	Eingeleitet	Credit Suisse	Outperform
2021-03-12	Eingeleitet	Wolfe Research	Outperform
2020-03-04	Eingeleitet	Barclays	Overweight
2020-01-13	Eingeleitet	SunTrust	Buy
2019-11-13	Eingeleitet	BofA/Merrill	Buy
2019-03-18	Hochstufung	Morgan Stanley	Underweight → Equal-Weight
2018-09-17	Eingeleitet	Goldman	Neutral
2018-09-10	Eingeleitet	Morgan Stanley	Underweight
2018-05-11	Bestätigt	Needham	Buy
2017-10-17	Bestätigt	Needham	Buy
2017-10-17	Bestätigt	RBC Capital Mkts	Outperform
2017-10-16	Bestätigt	SunTrust	Buy
2017-09-22	Herabstufung	Leerink Partners	Outperform → Mkt Perform
2017-09-15	Eingeleitet	RBC Capital Mkts	Outperform
2017-09-12	Bestätigt	Needham	Buy
2017-07-14	Eingeleitet	SunTrust	Buy
2017-03-31	Eingeleitet	Needham	Buy
2017-03-16	Eingeleitet	Oppenheimer	Perform
2017-02-28	Herabstufung	Stifel	Buy → Hold
2016-11-03	Eingeleitet	Deutsche Bank	Buy
2016-10-10	Hochstufung	Piper Jaffray	Neutral → Overweight
2016-09-15	Bestätigt	Stifel	Buy

Alle ansehen

Exelixis Inc Aktie (EXEL) Neueste Nachrichten

08:44 AM

Why Exelixis Inc. (EX9) stock could be next leader2025 Price Action Summary & Free High Return Stock Watch Alerts - mfd.ru

08:44 AM

04:06 AM

Illinois Municipal Retirement Fund Boosts Position in Exelixis, Inc. $EXEL - MarketBeat

04:06 AM

01:59 AM

Exelixis (NASDAQ:EXEL) Downgraded by Wall Street Zen to "Buy" - MarketBeat

01:59 AM

Feb 13, 2026

Aug Wrap: What is the earnings history of Exelixis IncWeekly Earnings Recap & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn

Feb 13, 2026

Assetmark Inc. Has $131.99 Million Stock Position in Exelixis, Inc. $EXEL - MarketBeat

Feb 13, 2026

Exelixis (EXEL) Q4 2025 Earnings Call Transcript - AOL.com

Feb 13, 2026

Feb 12, 2026

Exelixis stock price target raised to $54 from $52 at H.C. Wainwright - Investing.com Nigeria

Feb 12, 2026

Exelixis (EXEL) Receives a Buy from Stephens - The Globe and Mail

Feb 12, 2026

RBC Capital Sticks to Its Hold Rating for Exelixis (EXEL) - The Globe and Mail

Feb 12, 2026

Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL) and OrganiGram Holdings (OGI) - The Globe and Mail

Feb 12, 2026

Exelixis Reports Solid Earnings-Are New Highs Back on the Table? - Finviz

Feb 12, 2026

Exelixis Reports Solid Earnings—Are New Highs Back on the Table? - MarketBeat

Feb 12, 2026

Exelixis stock price target raised to $54 from $52 at H.C. Wainwright By Investing.com - Investing.com South Africa

Feb 12, 2026

Westover Capital Advisors LLC Grows Stake in Exelixis, Inc. $EXEL - MarketBeat

Feb 12, 2026